Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration

2011 ◽  
Vol 151 (2) ◽  
pp. 131-138 ◽  
Author(s):  
Ziyi Wen ◽  
Zhiqiang Yan ◽  
Kaili Hu ◽  
Zhiqing Pang ◽  
Xufei Cheng ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Intranasal Administration ◽  
Brain Delivery ◽  
Pharmacodynamic Study

Intranasal administration of endometrial mesenchymal stem cells as a suitable approach for Parkinson’s disease therapy

2019 ◽  
Vol 46 (4) ◽  
pp. 4293-4302 ◽  
Author(s):  
Saeid Bagheri-Mohammadi ◽  
Behrang Alani ◽  
Mohammad Karimian ◽  
Rana Moradian-Tehrani ◽  
Mahdi Noureddini
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Mesenchymal Stem Cells ◽  
Intranasal Administration ◽  
Disease Therapy

GOCOVRI® (amantadine) extended-release capsules in Parkinson's disease

2021 ◽  
Author(s):  
Thomas Müller
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Motor Behavior ◽  
Brain Delivery ◽  
Antiviral Compound ◽  
Once Daily ◽  
Beneficial Effects ◽  
Central Monoamine ◽  
Preventive Effects

Amantadine is an old, antiviral compound, which moderately improves motor behavior in Parkinson's disease. Its current resurgence results from an innovative, delayed uptake and extended release amantadine hydrochloride capsule, given at bedtime once daily. It is the only approved compound for reduction of involuntary movements, so called dyskinesia, in fluctuating orally levodopa treated patients. It additionally ameliorates ‘off’-intervals characterized by impaired motor behavior. These beneficial effects result from higher and more continuous brain delivery of amantadine. Future clinical research is warranted on preventive effects of this amantadine capsule combined with enzyme blockers of central monoamine oxidase B and peripheral catechol-O-methyltransferase on motor complications in orally levodopa treated patients, as all these pharmacological principles support the concept of continuous dopamine substitution.

scholarly journals Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease

2009 ◽  
Vol 135 (2) ◽  
pp. 119-126 ◽  
Author(s):  
E. Garbayo ◽  
C.N. Montero-Menei ◽  
E. Ansorena ◽  
J.L. Lanciego ◽  
M.S. Aymerich ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Brain Delivery ◽  
Promising Strategy

Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson’s Disease

2019 ◽  
Vol 11 (48) ◽  
pp. 45276-45289 ◽  
Author(s):  
Tongkai Chen ◽  
Wei Liu ◽  
Sha Xiong ◽  
Dongli Li ◽  
Shuhuan Fang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Brain Delivery

Single Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in C57BL/6 Mice Models Early Preclinical Phase of Parkinson’s Disease

2009 ◽  
Vol 17 (2) ◽  
pp. 114-129 ◽  
Author(s):  
Rui D. S. Prediger ◽  
Aderbal S. Aguiar ◽  
Argelia Esperanza Rojas-Mayorquin ◽  
Claudia P. Figueiredo ◽  
Filipe C. Matheus ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Intranasal Administration ◽  
Preclinical Phase
Sign in / Sign up

Export Citation Format

Share Document